UNSPSC 51162347: Caffeine/pheniramine/phenylephrine/sodium citrate/sodium salicylate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.

UNSPSC 51162347 Caffeine/pheniramine/phenylephrine/sodium citrate/sodium salicylate is a Commodity code under which state and local governments procure pharmaceutical products and controlled substances for healthcare delivery to incarcerated individuals and community health populations. The Washington State Department of Corrections issued RFQ RFQQK13020 in September 2026 seeking parenteral products, services, and equipment—including parenteral nutrition solutions (TPN and PPN), intravenous solutions, and other parenteral products including controlled substances—for delivery to eight correctional facilities across Washington state, with response due October 7, 2026. The scope requires vendors to demonstrate documented experience preparing and delivering IV solutions, monitoring patient lab results, and adjusting nutrition preparations, with strict delivery timelines (PN bags within 24 hours of order, other parenteral products within 8 hours). DOC anticipates selecting multiple contractors and may award up to three bidders per region. Issuing bodies under this code include state corrections departments and county health authorities. The Washington DOC solicitation emphasizes participation from small businesses, minority-owned businesses, women-owned businesses, and veteran-owned businesses under state set-aside programs, with a 5% Small and Diverse Business Goal and subcontractor inclusion requirements.

Recent activity centers in Washington state and Florida. The Washington State Department of Corrections' RFQ represents the primary recent opportunity, covering three regions (West, Central, and East) with an initial contract term running November 26, 2026 through June 30, 2030 and pricing fixed for the first two years. Seminole County, Florida issued IFB 60459723LAS in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, though that solicitation targets opioid-response and community health rather than the parenteral pharmaceutical products nominally described by the code. The Washington opportunity carries more direct relevance to the code's pharmaceutical scope, requiring compliance with Washington State business licensure, Washington State Patrol NCIC clearance for all service personnel, and specified insurance including Commercial General Liability ($1 million per occurrence / $2 million aggregate), Professional Liability ($2 million per occurrence / aggregate), Business Automobile Liability ($1 million per occurrence / $2 million aggregate), and Cyber Liability ($2 million per occurrence / aggregate).